Navigation Links
Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
Date:2/28/2008

trials; manufacturing; regulatory approval requirements and process; the effort and expense necessary for further development of Kosan's product candidates, including the costs of bortezomib; intellectual property matters, including Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and other risk factors are discussed under "Risk Factors" in Kosan's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and other periodic filings with the SEC. Kosan expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Selected Financial Information

Condensed Statements of Operations

(in thousands, except per share amounts)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)

Total revenues $5,636 $5,710 $22,707 $13,506

Operating expenses:

Research and development 13,902 8,817 47,283 37,179

General and administrative 2,108 2,090 8,162 7,823

Total operating expenses 16,010 10,907 55,445 45,002

Loss from operations (10,374) (5,197) (32,738) (31,496)

Other income, net 893 638 4,080 2,027

Net loss
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Kosan Announces February 28, 2008 Conference Call and Webcast
2. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
3. Kosan Announces Third Quarter 2007 Financial Results
4. Kosan to Reacquire Epothilone Program From Roche
5. Kosan Biosciences to Host Research & Development Day on October 31, 2007
6. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
7. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
8. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
9. Wyeth Announces Executive Change in Finance Organization
10. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
11. Pharmacopeia Announces Management Team Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
(Date:3/5/2015)... Ohio (PRWEB) March 05, 2015 ... Gold Development Partner located in Northeast Ohio, today announced ... e2b teknologies to support its upgrade to the latest ... the largest independent group practice of its kind in ... and large volume of transactions, so efficiency and data ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Latest Clinical Information On Bioterrorism Threats 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... Annual Biotechnology Investor Conference, November 8, Features ... Small to Mid-cap Public Growth Companies Renowned Investment ... Stelios Papadopoulos, ... The Massachusetts Biotechnology,Council,s ninth annual MASS Opportunities Investor Conference, ...
... AACR press ... conference, ... biotechnology company discovering and developing the next wave of,antibody therapeutics, today ... an oral presentation on one of the six abstracts it,will present ...
... Varian Medical,Systems (NYSE: VAR ) ... market-leading,VariSeed(TM) brachytherapy seed planning software. VariSeed 8.0,incorporates ... of the,treatment. "The new features provide ... seeds in permanent seed implants," says Rebecca ...
Cached Biology Technology:2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 3Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 2Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 3Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 4Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 2Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 3
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... the portions of the heart damaged by a lack of ... avoid this scarring, which can harden the walls of the ... and eventually lead to heart failure. But new research from ... Medicine shows that interrupting this process can weaken heart function ...
... CAMDEN How the brain perceives color is one ... a stable perception of an object,s color as lighting conditions ... at RutgersCamden, has teamed up with psychologists from the University ... how this works. Allred conducted the research with ...
... This release is available in German . ... rails as far as they go. But nature also knows systems ... in a hamster wheel, a train caught up in such a ... Cluster of Excellence Nanosystems Initiative Munich have now succeeded in building ...
Cached Biology News:Scarring a necessary evil to prevent further damage after heart attack 2Rutgers-Camden researcher examines how the brain perceives shades of gray 2Rutgers-Camden researcher examines how the brain perceives shades of gray 3Perfect micro rings woven from muscle fibers 2Perfect micro rings woven from muscle fibers 3
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... pAcGHLT-A,B,C Baculovirus ... Set,pAcGHLT-XylE Baculovirus ... Powder,Thrombin Dilution ... Cocktail,Insect Cell ...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
... been developed to significantly increase the shelf ... Stability is increased at room temperature storage ... This product is subjected to 0.2 micron ... This formulation insures consistently high levels ...
Biology Products: